Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AGN-229666 · 3 trials · 2 indications
Ocular itching was assessed by the participant 8 hours after AGN-229666 and vehicle administration and 4 hours after olopatadine administration, 5 minutes post allergen challenge using a 0 to 4 scale with 0.5 grade increments where: 0=none (no itching) to 4.0=incapacitating itch with an irresistible urge to rub (worst). Data from Days 1 and 15 were pooled together and averaged.
Ocular itching frequency is assessed on a 6-poing scale, where 0 = did not occur, 1 = once in 3 days, 2 = twice in 3 days, 3 = once every day, 4 = 2 or more times every day, and 5 = virtually all the time over the past 3 days. Ocular itching frequency is evaluated over the 3 days prior to the visit. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.
The participant evaluated ocular itching in both eyes 5 minutes post conjunctival allergen challenge (CAC) (8 hours post-dose) at Day 1 using a 9-point scale in half-unit increments where: 0=none to 4=incapacitating itch with an irresistible urge to rub. The score for each participant was the average of the score of both eyes.
| Arm | Type | Description |
|---|---|---|
| AGN-229666 | EXPERIMENTAL | One drop of AGN-229666 in each eye on Days 1 and 15. |
| Vehicle | PLACEBO_COMPARATOR | One drop of Vehicle to AGN-229666 in each eye on Days 1 and 15. |
| Olopatadine | ACTIVE_COMPARATOR | One drop of olopatadine in each eye on Days 1 and 15. |
| AGN-229666/Olopatadine | OTHER | One drop of AGN-229666 in one eye and one drop of olopatadine in the other eye on Days 1 and 15. |
| AGN-229666/Vehicle | OTHER | One drop of AGN-229666 in one eye and one drop of Vehicle to AGN-229666 in the other eye on Days 1 and 15. |
| AGN-229666 Dose A | EXPERIMENTAL | One drop of AGN-229666 Dose A into each eye on Day 1 and Day 15. |
| AGN-229666 Dose B | EXPERIMENTAL | One drop of AGN-229666 Dose B into each eye on Day 1 and Day 15. |
| vehicle of AGN-229666 | PLACEBO_COMPARATOR | One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15. |
| Name | Type | Description |
|---|---|---|
| AGN-229666 | DRUG | One drop of AGN-229666 in the eye on Days 1 and 15. |
| Vehicle to AGN-229666 | DRUG | One drop of Vehicle to AGN-229666 in the eye on Days 1 and 15. |
| Olopatadine | DRUG | One drop of olopatadine in the eye on Days 1 and 15. |
| vehicle of AGN-229666 | OTHER | One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15. |
Inclusion Criteria: -Japanese patients living in Japan with a history of allergic conjunctivitis. Exclusion Criteria: * Presence of active eye infection (bacterial, viral, or fungal) * History of an eye herpetic infection.
AGN-229666 is an investigational small molecule being developed by AbbVie Inc. (ABBV) for the treatment of allergic conjunctivitis, including seasonal and perennial allergic conjunctivitis. It is administered as an ophthalmic solution. The drug is currently in clinical development and has not been approved by regulatory authorities.
The specific molecular target of AGN-229666 has not been disclosed in available information. It is a small molecule developed for ophthalmic use in allergic conjunctivitis, but its mechanism of action is not publicly detailed.
AGN-229666 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The drug is an investigational ophthalmic solution intended for the treatment of allergic conjunctivitis.
AGN-229666 has completed Phase 2 and Phase 3 clinical trials. The Phase 2 trial (NCT01754766) was completed, and two Phase 3 trials (NCT02082262 and NCT02161146) were also completed. The drug is investigational and has not received FDA approval.
AGN-229666 has been studied in three completed clinical trials in Japan: NCT01754766 (Phase 2, 90 patients), NCT02082262 (Phase 3, 140 patients), and NCT02161146 (Phase 3, 240 patients). All trials were randomized, double-blind, and placebo-controlled, with no active trials currently ongoing.
No alternative names for AGN-229666 have been reported. The drug is identified solely by its code name AGN-229666 in clinical trial registries and development information.